Zydus Life shares gain on partnership with Swiss biopharmaceutical company

Zydus Lifesciences

Zydus Lifesciences share price gained in the opening trade on December 24 following the company's wholly owned subsidiary entered into a strategic partnership with Swiss biopharmaceutical company.

At 09:18am, Zydus Lifesciences was quoting at Rs 930.35, up Rs 2.25, or 0.24 percent, on the BSE.

Bioeq AG and Zydus Lifesciences' wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq’s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO, an interchangeable biosimilar of Lucentis (Ranibizumab) for the US market.

The biologics license application (BLA) for NUFYMCO has been approved by US Food and Drug Administration (USFDA) on December 18, 2025.

Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO in the US market.

Catch all the market action on our live blog

Last week, the company signed an agreement with Myriad Genetics, where Zydus will be introducing MyRisk Hereditary Cancer Test, MyChoice HRD Plus, Homologous Recombination Deficiency (HRD) Test and Prolaris Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India.

Also, Sentynl Therapeutics, Inc., a US-based biopharmaceutical company wholly-owned by Zydus Lifesciences, announced that the US Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application for copper histidinate (CUTX-101), intended to treat Menkes disease in pediatric patients.